Importance: Retinopathy of prematurity (ROP) is an important risk factor for blindness in children due to neovascularization (NV). Hypoxia stimulates the formation of NV, as retinal hypoxia affects the stability and function of hypoxia-inducible factor (HIF) transcription factors. The purpose of this study is to study the mechanism of ROP and provide theoretical basis for clinical treatment of ROP. Objective: In the present study, we used a mouse model of oxygen-induced retinopathy (OIR) to demonstrate the effects of the HIF-1α inhibitor PX-478 on OIR, and to determine its mechanism of action, to provide a theoretical basis for the clinical treatment of ROP. Materials and Methods: The OIR mouse model was induced by exposing neonatal mouse pups and their mothers to 75 ± 5% oxygen from postnatal day 7 (P7) to P12, before being returned to room air from P12 to P17. Flat mount analyses were performed at P12 and P17. Hif1a, Hif2a, Hif3a, and Vegfa mRNA were detected by reverse transcription-polymerase chain reaction in OIR mice at P12 and P17. Hif1a and Vegfa mRNA were detected in OIR mice at P12 and P17 treatment with PX-478. Western blot analyses were used to assess the levels of HIF-1α, VEGF-A, and EPO before and after treatment with PX-478 at P12 and P17. Results:Hif1a mRNA was increased in OIR mice at P12 and P17, while Vegfa mRNA was increased at P12 and P17. HIF-1α, VEGF-A, and EPO protein levels were increased in OIR mice at P12 and P17, as compared to control mice at the same age (all p < 0.05). Inhibition of HIF-1α by injection of PX-478 in OIR mice (P9–P16) caused a decrease in the retinal avascular area at P12 and P17 (both p < 0.05), NV areas at P17 (p < 0.05), Vegfa mRNA decreased at P12 and P17, as compared to control mice (p < 0.05), and VEGF-A and EPO protein levels at P12 and P17, as compared to control mice. Our study found that there were PX-478 both retina and vitreous body of OIR. Inhibition of HIF-1α by injection of PX-478 in OIR mice caused a decrease in the retinal avascular area at P12 and P17, NV areas decreased at P17, VEGF-A and EPO protein levels at P12 and P17. Endothelial cell migration assays and cell tube formation indication PX-478 attenuate cell migration and significantly weakened the cell cavity formation under the condition of hypoxia. Conclusion: HIF-1α plays a main role in OIR and can be considered a therapeutic target in OIR by suppressing downstream angiogenic factors, PX-478 decreasing the retinal avascular area and NV.

1.
Ashton
N
,
Ward
B
,
Serpell
G
.
Effect of oxygen on developing retinal vessels with particular reference to the problem of retrolental fibroplasia
.
Br J Ophthalmol
.
1954
Jul
;
38
(
7
):
397
432
.
[PubMed]
0007-1161
2.
Celebi
AR
,
Petricli
IS
,
Hekimoglu
E
,
Demirel
N
,
Bas
AY
.
The incidence and risk factors of severe retinopathy of prematurity in extremely low birth weight infants in Turkey
.
Med Sci Monit
.
2014
Sep
;
20
:
1647
53
.
[PubMed]
1234-1010
3.
Stahl
A
,
Connor
KM
,
Sapieha
P
,
Chen
J
,
Dennison
RJ
,
Krah
NM
, et al.
The mouse retina as an angiogenesis model
.
Invest Ophthalmol Vis Sci
.
2010
Jun
;
51
(
6
):
2813
26
.
[PubMed]
0146-0404
4.
Goldenberg
RL
,
Culhane
JF
,
Iams
JD
,
Romero
R
.
Epidemiology and causes of preterm birth
.
Lancet
.
2008
Jan
;
371
(
9606
):
75
84
.
[PubMed]
0140-6736
5.
Liu
Q
,
Yin
ZQ
,
Ke
N
,
Chen
L
,
Chen
XK
,
Fang
J
, et al.
Incidence of retinopathy of prematurity in southwestern China and analysis of risk factors
.
Med Sci Monit
.
2014
Aug
;
20
:
1442
51
.
[PubMed]
1234-1010
6.
Austeng
D
,
Karin
BM
.
Källen, U.W. Ewald, P.G. Jakobsson, G.E. Holmström, Incidence of retinopathy of prematurity in infants born before 27 weeks’ estation in Sweden
.
Arch Ophthalmol
.
2009
;
127
:
1315
9
.
[PubMed]
0003-9950
7.
Hennig
R
,
Goepferich
A
.
Nanoparticles for the treatment of ocular neovascularizations
.
Eur J Pharm Biopharm
.
2015
Sep
;
95
Pt B
:
294
306
.
[PubMed]
0939-6411
8.
Cavallaro
G
,
Filippi
L
,
Bagnoli
P
,
La Marca
G
,
Cristofori
G
,
Raffaeli
G
, et al.
The pathophysiology of retinopathy of prematurity: an update of previous and recent knowledge
.
Acta Ophthalmol
.
2014
Feb
;
92
(
1
):
2
20
.
[PubMed]
1755-375X
9.
Carroll
VA
,
Ashcroft
M
.
Role of hypoxia-inducible factor (HIF)-1alpha versus HIF-2alpha in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of von Hippel-Lindau function: implications for targeting the HIF pathway
.
Cancer Res
.
2006
Jun
;
66
(
12
):
6264
70
.
[PubMed]
0008-5472
10.
Caprara
C
,
Grimm
C
.
From oxygen to erythropoietin: relevance of hypoxia for retinal development, health and disease
.
Prog Retin Eye Res
.
2012
Jan
;
31
(
1
):
89
119
.
[PubMed]
1350-9462
11.
Smith
LE
,
Wesolowski
E
,
McLellan
A
,
Kostyk
SK
,
D’Amato
R
,
Sullivan
R
, et al.
Oxygen-induced retinopathy in the mouse
.
Invest Ophthalmol Vis Sci
.
1994
Jan
;
35
(
1
):
101
11
.
[PubMed]
0146-0404
12.
Connor
KM
,
Krah
NM
,
Dennison
RJ
,
Aderman
CM
,
Chen
J
,
Guerin
KI
, et al.
Quantification of oxygen-induced retinopathy in the mouse: a model of vessel loss, vessel regrowth and pathological angiogenesis
.
Nat Protoc
.
2009
;
4
(
11
):
1565
73
.
[PubMed]
1754-2189
13.
Masoud
GN
,
Li
W
.
HIF-1α pathway: role, regulation and intervention for cancer therapy
.
Acta Pharm Sin B
.
2015
Sep
;
5
(
5
):
378
89
.
[PubMed]
2211-3835
14.
Shortt
AJ
,
Howell
K
,
O’Brien
C
,
McLoughlin
P
.
Chronic systemic hypoxia causes intra-retinal angiogenesis
.
J Anat
.
2004
Nov
;
205
(
5
):
349
56
.
[PubMed]
0021-8782
15.
Subhani
S
,
Vavilala
DT
,
Mukherji
M
.
HIF inhibitors for ischemic retinopathies and cancers: options beyond anti-VEGF therapies
.
[Review]
.
Angiogenesis
.
2016
Jul
;
19
(
3
):
257
73
.
[PubMed]
0969-6970
16.
Gao
X
,
Wang
YS
,
Li
XQ
,
Hou
HY
,
Su
JB
,
Yao
LB
, et al.
Macrophages promote vasculogenesis of retinal neovascularization in an oxygen-induced retinopathy model in mice
.
Cell Tissue Res
.
2016
Jun
;
364
(
3
):
599
610
.
[PubMed]
0302-766X
17.
Welsh
S
,
Williams
R
,
Kirkpatrick
L
,
Paine-Murrieta
G
,
Powis
G
.
Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1alpha
.
Mol Cancer Ther
.
2004
Mar
;
3
(
3
):
233
44
.
[PubMed]
1535-7163
18.
Ozaki
H
,
Yu
AY
,
Della
N
,
Ozaki
K
,
Luna
JD
,
Yamada
H
, et al.
Hypoxia inducible factor-1alpha is increased in ischemic retina: temporal and spatial correlation with VEGF expression
.
Invest Ophthalmol Vis Sci
.
1999
Jan
;
40
(
1
):
182
9
.
[PubMed]
0146-0404
19.
Grimm
C
,
Hermann
DM
,
Bogdanova
A
,
Hotop
S
,
Kilic
U
,
Wenzel
A
, et al.
Neuroprotection by hypoxic preconditioning: HIF-1 and erythropoietin protect from retinal degeneration
.
Semin Cell Dev Biol
.
2005
Aug-Oct
;
16
(
4-5
):
531
8
.
[PubMed]
1084-9521
20.
Eric
A
.
Pierce, Robert L. Avery, Eliot D. Foley, Lloyd P. Aiello and Lois E. H. Smith. Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization
.
Proc Natl Acad Sci USA
.
1995
;
92
(
3
):
905
9
. 0027-8424
21.
Alon
T
,
Hemo
I
,
Itin
A
,
Pe’er
J
,
Stone
J
,
Keshet
E
.
Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity
.
Nat Med
.
1995
Oct
;
1
(
10
):
1024
8
.
[PubMed]
1078-8956
22.
Stone
J
,
Chan-Ling
T
,
Pe’er
J
,
Itin
A
,
Gnessin
H
,
Keshet
E
.
Roles of vascular endothelial growth factor and astrocyte degeneration in the genesis of retinopathy of prematurity
.
Invest Ophthalmol Vis Sci
.
1996
Feb
;
37
(
2
):
290
9
.
[PubMed]
0146-0404
23.
Chang
CC
,
Lin
MT
,
Lin
BR
,
Jeng
YM
,
Chen
ST
,
Chu
CY
, et al.
Effect of connective tissue growth factor on hypoxia-inducible factor 1α degradation and tumor angiogenesis
.
J Natl Cancer Inst
.
2006
Jul
;
98
(
14
):
984
95
.
[PubMed]
0027-8874
24.
Sean
F
.
Hackett, Stanley Wiegand,George Yancopoulos and Peter A. Campochiar. Angiopoietin-2 plays an important role in retinal angiogenesis
.
J Cell Physiol
.
2002
;
192
(
2
):
182
7
. 0021-9541
25.
Jo
N
,
Wu
GS
,
Rao
NA
.
Upregulation of chemokine expression in the retinal vasculature in ischemia-reperfusion injury
.
Invest Ophthalmol Vis Sci
.
2003
Sep
;
44
(
9
):
4054
60
.
[PubMed]
0146-0404
26.
Butler
JM
,
Guthrie
SM
,
Koc
M
,
Afzal
A
,
Caballero
S
,
Brooks
HL
, et al.
SDF-1 is both necessary and sufficient to promote proliferative retinopathy
.
J Clin Invest
.
2005
Jan
;
115
(
1
):
86
93
.
[PubMed]
0021-9738
27.
Villalvilla
A
,
Moro
M
,
Arruza
L
,
Redondo
S
,
Fernández-Cruz
A
,
Fernández-Durango
R
.
Circulating endothelial progenitor cells are reduced in rat oxygen-induced retinopathy despite a retinal SDF-1/CXCR4 and VEGF proangiogenic response
.
Life Sci
.
2012
Sep
;
91
(
7-8
):
264
70
.
[PubMed]
0024-3205
28.
Kelly
BD
,
Hackett
SF
,
Hirota
K
,
Oshima
Y
,
Cai
Z
,
Berg-Dixon
S
, et al.
Cell type-specific regulation of angiogenic growth factor gene expression and induction of angiogenesis in nonischemic tissue by a constitutively active form of hypoxia-inducible factor 1
.
Circ Res
.
2003
Nov
;
93
(
11
):
1074
81
.
[PubMed]
0009-7330
29.
Reich
SJ
,
Fosnot
J
,
Kuroki
A
,
Tang
W
,
Yang
X
,
Maguire
AM
, et al.
Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model
.
Mol Vis
.
2003
May
;
9
:
210
6
.
[PubMed]
1090-0535
30.
Morita
M
,
Ohneda
O
,
Yamashita
T
,
Takahashi
S
,
Suzuki
N
,
Nakajima
O
, et al.
HLF/HIF-2alpha is a key factor in retinopathy of prematurity in association with erythropoietin
.
EMBO J
.
2003
Mar
;
22
(
5
):
1134
46
.
[PubMed]
0261-4189
31.
Carmeliet
P
,
Moons
L
,
Luttun
A
,
Vincenti
V
,
Compernolle
V
,
De Mol
M
, et al.
Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions
.
Nat Med
.
2001
May
;
7
(
5
):
575
83
.
[PubMed]
1078-8956
32.
Jo
N
,
Mailhos
C
,
Ju
M
,
Cheung
E
,
Bradley
J
,
Nishijima
K
, et al.
Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization
.
Am J Pathol
.
2006
Jun
;
168
(
6
):
2036
53
.
[PubMed]
0002-9440
33.
Lin
M
,
Chen
Y
,
Jin
J
,
Hu
Y
,
Zhou
KK
,
Zhu
M
, et al.
Ischaemia-induced retinal neovascularisation and diabetic retinopathy in mice with conditional knockout of hypoxia-inducible factor-1 in retinal Müller cells
.
Diabetologia
.
2011
Jun
;
54
(
6
):
1554
66
.
[PubMed]
0012-186X
34.
Sun
K
,
Halberg
N
,
Khan
M
,
Magalang
UJ
,
Scherer
PE
.
Nils Halberg, Mahmood Khan, Ulysses J. Magalang, Philipp E. Scherera. Selective Inhibition of Hypoxia-Inducible Factor 1a Ameliorates Adipose Tissue Dysfunction
.
Mol Cell Biol
.
2013
;
33
(
5
):
904
17
.
[PubMed]
0270-7306
35.
Nobutaka
Doia
,
Ryohei
Ogawaa
,
Zheng-Guo
Cui
,
Takashi
Kondo
.
The acquired radio resistance in He La cells under conditions mimicking hypoxia was attenuated by a decreased expression of HIF subunit genes induced by RNA interference.
Experimental Cell Research.
2015
; 33:24 9-260.
36.
Kim
SH
,
Hwang
D
,
Park
H
,
Yang
EG
,
Chung
HS
,
Kim
SY
.
The action of HIF-3α variants on HIF-2α-HIF-1β heterodimer formation is directly probed in live cells
.
Exp Cell Res
.
2015
Aug
;
336
(
2
):
329
37
.
[PubMed]
0014-4827
37.
Weidemann
A
,
Krohne
TU
,
Aguilar
E
,
Kurihara
T
,
Takeda
N
,
Dorrell
MI
, et al.
Astrocyte hypoxic response is essential for pathological but not developmental angiogenesis of the retina
.
Glia
.
2010
Aug
;
58
(
10
):
1177
85
.
[PubMed]
0894-1491
38.
M.
Elizabeth Hartnett
,
MD.
Pathophysiology
and Mechanisms of Severe Retinopathy of Prematurity.
Ophtha.
2015
;
122
:
200
10
.
39.
Wang
H
,
Yang
Z
,
Jiang
Y
,
Flannery
J
,
Hammond
S
,
Kafri
T
, et al.
Quantitative analyses of retinal vascular area and density after different methods to reduce VEGF in a rat model of retinopathy of prematurity
.
Invest Ophthalmol Vis Sci
.
2014
Feb
;
55
(
2
):
737
44
.
[PubMed]
0146-0404
40.
Wu
WK
,
Llewellyn
OP
,
Bates
DO
,
Nicholson
LB
,
Dick
AD
.
IL-10 regulation of macrophage VEGF production is dependent on macrophage polarisation and hypoxia
.
Immunobiology
.
2010
Sep-Oct
;
215
(
9-10
):
796
803
.
[PubMed]
0171-2985
41.
Koh
MY
,
Spivak-Kroizman
T
,
Venturini
S
,
Welsh
S
,
Williams
RR
,
Kirkpatrick
DL
, et al.
Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1alpha
.
Mol Cancer Ther
.
2008
Jan
;
7
(
1
):
90
100
.
[PubMed]
1535-7163
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.